Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients - PubMed (original) (raw)

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients

Yu-Xiao Yang et al. Gastroenterology. 2004 Oct.

Abstract

Background & aims: Endogenous hyperinsulinemia in the context of type 2 diabetes mellitus is potentially associated with an increased risk of colorectal cancer. We aimed to determine whether insulin therapy might increase the risk of colorectal cancer among type 2 diabetes mellitus patients.

Methods: We conducted a retrospective cohort study among all patients with a diagnosis of type 2 diabetes mellitus in the General Practice Research Database from the United Kingdom. We excluded patients with <3 years of colorectal cancer-free database follow-up after the diabetes diagnosis as well as those insulin users who developed colorectal cancer after <1 year of insulin therapy. The remaining insulin users and the noninsulin-using type 2 diabetic patients were followed for the occurrence of colorectal cancer. Hazard ratios (HR) were determined in Cox proportional hazard analysis. A nested case-control study was conducted to perform multivariable analysis and to determine a duration-response effect.

Results: The incidence of colorectal cancer in insulin users (n = 3160) was 197 per 100,000 person-years, compared with 124 per 100,000 person-years in type 2 diabetes mellitus patients not receiving insulin (n = 21,758). The age- and sex-adjusted HR of colorectal cancer associated with > or =1 year of insulin use was 2.1 (95% CI: 1.2-3.4, P = 0.005). The positive association strengthened after adjusting for potential confounders. The multivariable odds ratio associated with each incremental year of insulin therapy was 1.21 (95% CI: 1.03-1.42, P = 0.02).

Conclusions: Chronic insulin therapy significantly increases the risk of colorectal cancer among type 2 diabetes mellitus patients.

PubMed Disclaimer

Cited by

Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan.
Tseng CH. Tseng CH. Hepatol Int. 2013 Jun;7(2):693-702. doi: 10.1007/s12072-012-9405-0. Epub 2012 Oct 6. Hepatol Int. 2013. PMID: 26201803
Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.
El-Zayadi AR, Anis M. El-Zayadi AR, et al. World J Gastroenterol. 2012 Jan 21;18(3):212-24. doi: 10.3748/wjg.v18.i3.212. World J Gastroenterol. 2012. PMID: 22294824 Free PMC article. Review.
A possible link between insulin glargine and malignancy: the facts.
Mollentze WF. Mollentze WF. Cardiovasc J Afr. 2009 Jul-Aug;20(4):216-8; discussion 218-9. Cardiovasc J Afr. 2009. PMID: 19701528 Free PMC article. No abstract available.
Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria.
Tonry CL, Evans RM, Ruddock MW, Duggan B, McCloskey O, Maxwell AP, O'Rourke D, Boyd RE, Watt J, Reid CN, Curry DJ, Stevenson M, Young MK, Jamison CS, Gallagher J, Fitzgerald SP, Lamont J, Watson CJ. Tonry CL, et al. Diabetes Metab Res Rev. 2022 Sep;38(6):e3546. doi: 10.1002/dmrr.3546. Epub 2022 May 22. Diabetes Metab Res Rev. 2022. PMID: 35578575 Free PMC article.
A drug repurposing method based on inhibition effect on gene regulatory network.
Li X, Liao M, Wang B, Zan X, Huo Y, Liu Y, Bao Z, Xu P, Liu W. Li X, et al. Comput Struct Biotechnol J. 2023 Sep 9;21:4446-4455. doi: 10.1016/j.csbj.2023.09.007. eCollection 2023. Comput Struct Biotechnol J. 2023. PMID: 37731599 Free PMC article.

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients - PubMed (original) (raw)